Intravenous Immunoglobulin Therapy in ICU-Managed Guillain–Barré Syndrome: Clinical Profile and Treatment Outcomes
Abstract
Background: Guillain–Barré Syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy
characterized by rapidly progressive weakness and variable clinical severity, frequently necessitating intensive
care support. Axonal variants, particularly in Indian populations, are associated with more severe disease, higher
ventilatory requirements, and poorer outcomes. Despite the established efficacy of intravenous immunoglobulin
(IVIG), morbidity and mortality remain significant among critically ill patients.
Objectives: To evaluate the demographic profile, clinical characteristics, electrophysiological subtypes, intensive
care course, and in-hospital outcomes of adult patients with GBS treated with IVIG in a tertiary-care intensive
care unit.
Methods: A retrospective observational case series was conducted from January to December 2025 in the ICU of
a tertiary-care center. Adult patients (≥18 years) meeting Brighton diagnostic criteria (Levels 1–3) and treated
with standard IVIG therapy (0.4 g/kg/day for 5 days) were included. Data on demographics, antecedent events,
clinical presentation, electrophysiological subtype, need for mechanical ventilation, ICU duration, complications,
and outcomes were analyzed using descriptive statistics.
Results: A total of 15 patients were included (mean age: 35.5 years; 66.7% male). Antecedent infections were
identified in 73.3% of cases. The predominant electrophysiological subtype was Acute Motor Axonal Neuropathy
(53.3%), followed by Acute…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 15 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.